Matica Biotechnology Inc., a US subsidiary of South Korea-based biotechnology company CHA Biotech, has signed a strategic partnership agreement with the National Center for Therapeutics Manufacturing at Texas A&M University to accelerate the development of cell and gene therapies, or CGT.
This collaboration merges Matica Bio’s manufacturing and regulatory expertise with NCTM’s early-stage research and development capabilities. The two organizations aim to provide an integrated service platform that supports CGT innovators from early research through clinical trials and commercialization — all within College Station, Texas.
Matica Bio operates a state-of-the-art CGT Contract Development and Manufacturing Organization facility equipped with the Ambr 250 bioreactor and single-use systems. Its proprietary HEK293-based cell line, MatiMax, enhances production efficiency and reduces development timelines and costs.
NCTM, part of the Texas A&M Engineering Experiment Station, plays a key role in supporting biotechnology research and workforce development. Through this partnership, it will offer bench-to-pilot scale support to academic labs, start-ups and biotech firms working on early-stage CGT programs.
“This partnership creates powerful synergy between academic innovation and industrial execution,” said Paul Kim, CEO of Matica Biotechnology. “It enables faster, more cost-effective CGT development and reduces market entry barriers.”
Director of NCTM Dr. Baley Reeves added, “Our collaboration with Matica Bio will help deliver cutting-edge therapies to patients more efficiently by streamlining production and reducing costs.”
hyelimchung@heraldcorp.com
